Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. - Wikidata - awgldk - TriplyDB

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.

http://www.wikidata.org/entity/Q38441000

about

The year in cardiology 2014: acute coronary syndromes Imaging plaques to predict and better manage patients with acute coronary events Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.Leveraging human genetics to guide drug target discovery.Novel biomarkers for cardiovascular risk prediction.The (G>A) rs11573191 polymorphism of PLA2G5 gene is associated with premature coronary artery disease in the Mexican Mestizo population: the genetics of atherosclerotic disease Mexican study.The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.Anti-inflammatory therapies for cardiovascular disease Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation.Evolving targets for lipid-modifying therapy A new era of secreted phospholipase A₂ Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award Lecture Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation.Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL.Qing-Xin-Jie-Yu Granules in addition to conventional treatment for patients with stable coronary artery disease (QUEST Trial): study protocol for a randomized controlled trial Using genetic variation for establishing causality of cardiovascular risk factors: overcoming confounding and reverse causality.The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.Lipid pharmacotherapy for treatment of atherosclerosis.New therapies for coronary artery disease: genetics provides a blueprint.Critical appraisal of inflammatory markers in cardiovascular risk stratification.Why do statins reduce cardiovascular disease more than other lipid modulating therapies?Biomarkers of plaque instability.Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.Mendelian randomisation applied to drug development in cardiovascular disease: a review.Advances in non-invasive drug delivery for atherosclerotic heart disease.MethotrexaTE THerapy in ST-Segment Elevation MYocardial InfarctionS.Genetic risk factors and Mendelian randomization in cardiovascular disease.Role for combination therapy in diabetic dyslipidemia.The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.Investigational new drugs for the treatment of acute coronary syndrome.Secretory phospholipase A2 group IIA modulates insulin sensitivity and metabolism.Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases.Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.Inflammatory processes in cardiovascular disease: a route to targeted therapies.Genetics-Current and Future Role in the Prevention and Management of Coronary Artery Disease.Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?

P2860

Q26865907-809F0E3C-3295-48A5-972B-175736330245 Q26999943-8FA9E3F0-DCD9-4F7C-BB7B-0173F22CE600 Q30234302-205E4411-57D0-459E-B097-DE367E11B8C8 Q30245007-5759DD40-23FE-4BD6-AACB-6F4D4137D652 Q33615459-82A0E0AB-F983-4587-B814-554834D9BB11 Q33736168-9F3F524F-047C-4D50-833A-6506A512AFE4 Q33838927-0532BFC1-5238-461B-8929-39C7A7638466 Q33923169-36201111-426B-4E2C-A6C0-599B926451A1 Q33945132-8043A26F-B394-4210-9C04-5077376E63A1 Q34137872-5F633F2C-6CF9-4223-86B6-6BBE50F565E4 Q34418471-05C66E6F-B410-4EAA-94C9-E8E97EFE682B Q34524163-2B9790EF-46DD-47A7-AC92-5E32905ACF4A Q34880292-43DD1675-A16E-478D-9C14-03C39A064E4D Q35776615-DA44DAB8-2564-4E71-A003-B3D42442D2AD Q35881759-69000874-B0B0-47F3-9F6F-E0304ABAC5C9 Q36171277-45AFB0C1-1E3D-49D7-AC79-48CC18159EB6 Q36681188-D7E4052E-5FF5-4D19-B583-CB067063BC7C Q37258254-CF5EFE2D-85B3-4892-9851-3B43A64243A0 Q37638455-75587187-6C9F-4099-AEE4-6FD6AF892FB9 Q38201960-F9265E9E-F858-4991-A7EF-33C4CBAA7585 Q38202198-1447A87C-7C0E-42FC-A0AC-4C88EEDE94D3 Q38217732-13A89E05-11A8-45D5-B0A5-E12E8704673F Q38219501-FBC139AD-05A9-47D4-AB99-5A664DF6A980 Q38253965-63E8EA11-F5DD-472A-BA77-71553385E269 Q38261198-48044D77-2D6B-4A8A-9FE6-5B5E878EEEE5 Q38265002-665D4FC5-386F-4F95-80A3-98BB36117BA2 Q38290764-080CA9B1-3F69-4217-A44E-C1A5DA0C1CC6 Q38317205-F6255CAF-F524-48F4-A5A4-BE2C42CE0498 Q38379218-04CAE2AF-D93D-4BA3-9204-45ED2C3544C2 Q38430758-E5AC6095-0012-4889-ABC2-A5C89B587221 Q38430793-D0F543B7-D416-43A1-9860-F82AF3BC855A Q38593722-F6DA552B-5C40-4D5E-B71D-D34B6E7999D7 Q38594609-733CC673-300C-48A3-80F0-2914D1DD22EF Q38701624-B6449BD7-5274-47E9-9077-40FC6FB7044D Q38707328-D1F3C603-6BC2-4C9B-9A55-202274F89D90 Q38749160-7A97DBD5-33B7-4728-87B5-1CDF25B6156E Q38786058-13FFB5D3-978A-426A-9690-CB692935BA50 Q38788685-9971DD69-E7B4-4D3C-A578-5B4496D5D2C3 Q38798354-25804D39-75E6-42E2-9DD9-C82444A0A5BA Q38836998-50899AF6-75C0-4757-9895-6E75C50742B3

P2860

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.

http://www.wikidata.org/entity/Q38441000

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Varespladib and cardiovascular ...... -16 randomized clinical trial.

@en

type

label

Varespladib and cardiovascular ...... -16 randomized clinical trial.

@en

prefLabel

Varespladib and cardiovascular ...... -16 randomized clinical trial.

@en

P1433

Q38441000-AABCF445-A208-47C0-AA87-21A4E3061F8D

P1476

Q38441000-5865B3EA-01D5-4A37-866A-01DCFCEFE3A3

P2093

Q38441000-23F8BEE1-4F2A-4C8B-9005-455BC6DFC0A8

Q38441000-2C0F1945-CA20-4373-BA80-D4BAC30F9AF4

Q38441000-2F4C46DE-67C1-402F-91B3-36BAF03C1A37

Q38441000-5F567CB9-CAC7-4913-AC2E-ADC11704740F

Q38441000-76BFE0B5-9A3A-4CEF-87EB-82D85A6A6D35

Q38441000-87529C89-EFB1-422B-A8C7-330259CACDC7

Q38441000-9D3E31D0-8E3C-4C08-9943-9B3DA741F75E

Q38441000-A71702D9-66BE-4433-A452-649450D70F3A

Q38441000-ACED2B41-698E-4393-9060-996A16BE90F9

Q38441000-BA22B50D-356C-4407-A59E-5FD8E018F3CA

P304

Q38441000-919DA039-1827-446D-A42E-8CF456B7C562

P31

Q38441000-E7F83778-D7D4-4B75-9C2B-2BD604F46548

P356

Q38441000-0DB8B6BF-C2A9-40BA-8CEE-4982639B57E5

P407

Q38441000-D548543F-86D2-48DB-B918-47941FC5B392

P433

Q38441000-78C514E5-8AD5-4051-BE7E-7031D9BABCEB

P478

Q38441000-D985EABA-0421-438A-B582-CC848ADC8A93

P50

Q38441000-D47E88F6-683A-4E94-93CF-EB03A3529D20

Q38441000-F2CA1453-51DF-4055-AE9B-2825BEB6374A

P577

Q38441000-D1EE15FE-DF11-4B8B-80C7-105D7CADBE22

P698

Q38441000-A64A13D0-91D5-40F4-86F6-A10E48F3193C

P356

JAMA.2013.282836

P1433

Journal of the American Medical Association

P1476

Varespladib and cardiovascular ...... -16 randomized clinical trial.

@en

P2093

Dianna Bash

http://www.w3.org/2001/XMLSchema#string

Gregory G Schwartz

http://www.w3.org/2001/XMLSchema#string

J Wouter Jukema

http://www.w3.org/2001/XMLSchema#string

John J P Kastelein

http://www.w3.org/2001/XMLSchema#string

Matthew A Cavender

http://www.w3.org/2001/XMLSchema#string

R Scott Wright

http://www.w3.org/2001/XMLSchema#string

Robert S Rosenson

http://www.w3.org/2001/XMLSchema#string

Stephen J Nicholls

http://www.w3.org/2001/XMLSchema#string

Steven E Nissen

http://www.w3.org/2001/XMLSchema#string

VISTA-16 Investigators

http://www.w3.org/2001/XMLSchema#string

P304

252-262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2013.282836

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

311

http://www.w3.org/2001/XMLSchema#string

P50

A Michael Lincoff

Danielle M Brennan

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24247616

http://www.w3.org/2001/XMLSchema#string